Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
Last trade$0.332
Day change-$0.0269 (-7.50%)
Day range$0.276 – $0.42
Volume77,239
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for GELS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for GELS.
Recent news
Company coverage with links to the original publishers.
U.S. stock futures declined on Wednesday as investors await a Supreme Court ruling on Trump's tariff authority. The Consumer Price Index rose 2.7% year-over-year in December, matching expectations, while core CPI came in slightly below forecasts at 2.6%. Major indices including the Dow Jones, S&P 500, and Nasdaq 100 all declined in premarket trading. Notable movers include Wells Fargo reporting earnings, BP announcing a $5 billion writedown in energy transition businesses, WeRide launching a robotaxi service on WeChat, and TG Therapeutics providing optimistic 2026 guidance.
Gelteq Limited, a global biotechnology company, has appointed Matthew Jones as Head of Sports Performance to oversee the growth, outreach, and customer strategy of its sports vertical. Jones, a leading sports dietitian, will focus on expanding the adoption of Gelteq's gel-based delivery platform in the sports industry.
Gelteq Limited, a global biotechnology company, announced the closing of its initial public offering of 1,300,000 ordinary shares at a public offering price of US$4.00 per share. The company intends to use the net proceeds from the offering for various purposes, including funding certain manufacturing, marketing, and research and development activities.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.